Happy 25th Anniversary Hematologics!

Urgent Update on Paraffin FISH samples, click here

  • Submit slide mounted paraffin sections only (marked H&E,  5 to 8 paraffin sections cut at 4 microns)
  • New TAT will be 3-7 days

 

Update March 25, 2020
COVID-19: Hematologics is committed to staying operational and serving our clients and their patients throughout this challenging time. As an essential service provider, Hematologics will remain open and fully functional throughout the ‘Stay at Home’ edict issued by The Governor of Washington State. We are taking significant steps to protect our staff, supply chains, and lines of communication with our clients. We have been actively monitoring our operations and can see the potential for TATs to extend beyond our current stated limits. We want to assure you that we will take every possible measure to ensure there is little to no disruption to our reporting schedules. However, if you feel there has been a delay and you are in need of a result, please do not hesitate to contact us. We will review the case with you and provide you with a preliminary result (if possible) or an anticipated report date and time.
We thank you all for your understanding and willingness to work with us to continue to provide the necessary care for all patients seen at Hematologics.

 

 

New FISH Probes added to the test menu:

TNFRSF14/ABL2:  used in Pediatric-type Follicular Lymphoma
BLL-11q:  used in Burkitt-like Lymphoma w/ 11 Aberration
DUSP22/IRF4 +Cen6:  used in Large B-cell Lymphoma with IRF4 rearrangement

New HematoLogics Publication and the instrumental use of FACS FISH, provides the detection of BCR/ABL-1 positive T-cell lymphoblastic leukemia arising in early lymphoid progenitor cells and the possible treatment implications.

Click here to learn more

New Test Announcement: CD33, a new biomarker that determines response to Mylotarg therapy now available at HematoLogics.

Click here to learn more

HematoLogics in conjunction with Children’s Oncology Group discovered a new phenotype of Acute Myeloid Leukemia called RAM.

Click here to learn more

HematoLogics is the recognized leader for Measurable Residual Disease testing for Acute Leukemia. Click here to view the recently published data.

HematoLogics has increased the specificity of MYD88 L265P by 33% and the sensitivity of CXCR4 by 63% through Flow Cytometric Cell Sorting of Plasma and Lymphoid cells. Click to learn more.

Residual Disease

Small numbers of residual malignant cells are associated with clinical relapse at a later date.  Hematologics is the leader in residual disease testing by flow cytometry using a Difference from Normal approach.  We also offer a comprehensive menu of quantitative PCR assays for translocations, flow cytometric cell sorting, and molecular profiling by DNA analysis.

Cytopenias/MDS

Hematologics has found that 30% of all cytopenias are associated with abnormal myeloid cells.  With our unique Difference from Normal Flow Cytometric analysis, we assign an MDS Flow score that is associated with Myelodysplastic syndromes. We also offer aCGH/SNP microarray (LOH), FISH panels, cytogenetic karyotypes, and comprehensive DNA mutation panels.

Plasma Cells

Hematologics combines plasma cell enrichment and plasma cell sorting for FISH and aCGH/SNP  microarray  analysis for the diagnosis, prognosis and monitoring of plasma cell neoplasms.  For patients with concurrent monoclonal B-cell and plasma cell populations, we offer PCR IGH monoclonality profiling and MYD88 on the sorted populations to establish diagnosis.

Biopharm

Hematologics has extensive experience analyzing biopsies from patients on clinical trials, including those treated with novel therapies.  Please contact us to find out more how we can help clinical trial monitoring or assessment of new drug targets for the treatment of myeloid or lymphoid neoplasms.

Who We Are

Hematologics has assembled an in-house group of experts in each diagnostic field so that all testing is performed at Hematologics and not sent out to other specialty labs. This speeds up analysis and permits rapid response to unexpected findings due to communication between directors on every case.

 

What We Do

Hematologics provides immunophenotyping, cytogenetics, fluorescence in situ hybridization, molecular analysis studies and microscopic examination in our own state-of-the-art flow cytometric, cytogenetic and molecular biology laboratories. Send us a sample, and we will provide full interpretive reports.

 

Hematologics

Welcome to Hematolinx:

• Hematologics, Inc., now offers access to your patient specimen results through a secure internet interface.
• Review and compare patient history with current reports.
• Optional email notifications as specimen results become available.

To Become A Member:

Please call Hematologics for more details or call your local sales representative for an invitation.

This is a unique website which will require a more modern browser to work!

Please upgrade today!